Case history
In January 1965, a 70-year-old woman was admitted with a 9-day history of palpitations. She had been on digoxin for 3 years following an episode of mild cardiac failure, thought to be ischaemic in origin, at the time of a cholecystectomy; her previous health had been good.
On admission she had a tachycardia with a rate of 172/min, refractory to small doses of quinidine, so she was reverted by DC shock and discharged on procainamide. After reversion there were no abnormal signs: BP 150/90, ECG showed sinus rhythm, rate 70/min and right bundle branch block. eczematous dermatitis, pallor, lymphadenopathy and hepatosplenomegaly. She had a haemolytic anaemia, haemoglobin 10-2 g/100 ml with 5%4 reticulocytes, and bilirubin 1 2 mg/100 ml, a leucopenia 3200/mm3 and thrombocytopenia 51,000/mm3 (Fig. 2) . The skin improved with topical betamethasone valerate and she refused to allow any reduction in the dose of quinidine.
She remained relatively well for the next 18 months but came in again in October 1969 with a rash which had been present for a month. It was pruritic, erythematous and scaly covering the exposed surfaces of the body, with areas of skin atrophy and patches of follicular plugging. A diagnosis of lupus erythematosus was made and confirmed by skin biopsy. The liver was enlarged as before, though the spleen and lymph nodes were not palpable. Her haemoglobin was 10 g/100 ml, WBC 5000/mm3, platelets 87,OCO/ mm3, bilirubin 1 2 mg/100 ml, albumin 3-8 and globulin 2-1 g/100 ml. Her 162,000/mm3, albumin 40 g/100 ml, globulin 2-2 g/100 ml, bilirubin 2-4 mg, and urea 54 mg/100 ml. The ANF test remains weakly positive and the Coombs' test is positive.
Comment
Quinidine is known to cause hypersensitivity reactions and thrombocytopenia (Bishop, Spencer & Bethel, 1959) but has not hitherto been shown to cause SLE, although quinine, which is closely related chemically, has been incriminated. It is surprising that our patient had had procainamide without complications, since this drug frequently causes SLE (Fakhro, Ritchie & Lown, 1967) and is the most potent drug capable of activating lupus (Alarcon-Segovia, 1969). It was not the precipitating factor in our patient because the features of lupus did not appear until 18 months after the drug had been stopped. Previous series (Fakhro et al., 1967) have emphasized that the lupus syndrome develops during chronic therapy (3-22 months) with procainamide and regresses when the drug is stopped and that arthralgia is present in every instance, with pleurisy occurring in the majority.
Although SLE had developed, quinidine had to be continued since it was the only drug which controlled the tachycardia that on several occasions caused severe heart failure. When corticosteroids were added both her skin and general health improved, the white cells and platelets increased, though the haemolytic anaemia has persisted.
Drug-induced SLE is becoming well recognized. It resembles the spontaneous form clinically, serologically and histologically, and is probably more common in females. It occurs in an older age group who are more likely to be given the responsible drugs, and differs from the spontaneous form in that renal complications are less common. The prognosis, after withdrawal of the drug, is usually good. Theoretically the aetiology of SLE might be clarified from a knowledge of the drugs which cause this variant. However the many drugs responsible do not have anything in common except that many can cause hypersensitivity reactions and some may occasionally cause leucopenia, thrombocytopenia and haemolytic anaemia.
The reported cases of drug-induced lupus probably represent the tip of an iceberg. A positive ANF occurs in all instances of procainamide-induced lupus but serological abnormalities have been recorded in up to 65% of patients taking prccainamide (Dubois et al., 1968) and in 67% of tuberculous patients on isoniazid (Alarcon-Segovia, 1969) . Until the mode of action is understood, any drug might be suspect and presumably also any food additive. Some preparations shown to be responsible are no longer in common use but the risk should be remembered when considering long-term therapy with any of the following:-(1) Anticonvulsants: phenytoin, troxidone, primidone.
(2) Antibacterial and fungal agents: sulphonamides, penicillin, tetracycline, griseofulvin.
(3) Antituberculous therapy: streptomycin, PAS and isoniazid.
(4) Antirheumatic preparations: phenylbutazone, gold, long-term steroids.
(5) Cardiac depressants: procainamide, quinidine.
(6) Antithyroid drugs: methyl and propyl thiouracil.
(7) Hypotensives: hydralazine, methyldopa, reserpine.
(8) Others: antihistamines, chlorpromazine, oral contraceptives and quinine.
Any of these drugs may precipitate an exacerbation of SLE or explain the development of rashes, hepatosplenomegaly, arthropathies or blood dyscrasias. Awareness of this is important for the drug can then be stopped. Although the prognosis of drug-induced SLE is usually good, fatalities have been reported (Holley, 1961) .
